Challenge
A commercial-stage life sciences company was interested in entering the therapeutics markets to drive incremental top-line growth and drive synergies with the current portfolio of nutrition-based pediatrics products.
Approach
We initiated a situational assessment with the client to understand their strategic guardrails and priorities. Scimitar then generated a universe of <2K potential pediatric-focused assets within the client parameters and conducted a screening and prioritization exercise to short-list and rank attractive therapeutic classes for continued BD pursuit.
Impact
The client leveraged the multiple BD strategies we proposed to continue their exploration of external innovation to capture and integrate into their portfolio.
